Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay
- PMID: 35878802
- PMCID: PMC9307287
- DOI: 10.1016/j.ijid.2022.07.049
Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay
Abstract
Objectives: In this study, we aimed to characterize the SARS-CoV-2-specific T cell response detected by the QuantiFERON SARS-CoV-2 research use only assay in terms of accuracy and T cell subsets involved compared with a homemade interferon (IFN)-γ release assay (IGRA).
Methods: We evaluated T cell response by the standardized QuantiFERON SARS-CoV-2 tubes (antigen [Ag]1 and Ag2) and a homemade IGRA quantifying IFN-γ response to SARS-CoV-2 spike peptides (homemade-IGRA-SPIKE test). We evaluated the T cell subsets mediating the specific response using flow cytometry.
Results: We prospectively enrolled 66 individuals: COVID-19 or post-COVID-19 subjects and NO-COVID-19-vaccinated subjects, including healthy donors and immunocompromised subjects. The standardized kit detected 62.1% (41/66) of T cell responders. Ag2 tube showed a higher IFN-γ quantitative and qualitative response. Ag1 tube response was mainly mediated by CD4+ T cells; Ag2 tube response was mediated by CD4+ and CD8+ T cells. The homemade-IGRA-SPIKE test detected a higher number of responders (52/66, 78.8%) than the QuantiFERON SARS-CoV-2 assay (P = 0.056). The response was found in both T cell subsets, although a higher magnitude and response rate was observed in the CD4+ T cell subset.
Conclusion: The QuantiFERON SARS-CoV-2 response is mediated by CD4+ and CD8+ T cells. A lower number of responders is found compared with the homemade-IGRA-SPIKE test, likely because of the different peptide composition.
Keywords: COVID-19; IFN-γ release assay (IGRA), T cell response; QuantiFERON SARS-CoV-2 tubes; Spike peptides; Whole-blood.
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Conflict of Interest CT and CG received honoraria for speaking, manuscript writing, or educational events from Merck, Biogen, Roche, Novartis Sanofi, Celgene, and Almiral. EN participates on a data safety monitoring board or advisory board and receives fees for educational training from Gilead, Eli Lilly, GS, SOBI, and Roche. EN has a patent pending for raloxifene use in COVID-19 with Dompè Pharmaceutical. DG is a member of the advisory board of Biomerieux and Eli Lilly and received fees for educational training or consultancy from Almiral, Biogen, Cellgene, Diasorin, Janssen, Qiagen, and Quidel. All the other authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



Similar articles
-
Performance comparison of a flow cytometry immunoassay for intracellular cytokine staining and the QuantiFERON® SARS-CoV-2 test for detection and quantification of SARS-CoV-2-Spike-reactive-IFN-γ-producing T cells after COVID-19 vaccination.Eur J Clin Microbiol Infect Dis. 2022 Apr;41(4):657-662. doi: 10.1007/s10096-022-04422-7. Epub 2022 Feb 15. Eur J Clin Microbiol Infect Dis. 2022. PMID: 35165804 Free PMC article.
-
Performance of the Roche Elecsys® IGRA SARS-CoV-2 test for the detection and quantification of virus-reactive T cells in COVID-19-vaccinated immunosuppressed patients and healthy subjects.Eur J Clin Microbiol Infect Dis. 2024 Jul;43(7):1427-1436. doi: 10.1007/s10096-024-04852-5. Epub 2024 May 23. Eur J Clin Microbiol Infect Dis. 2024. PMID: 38777919 Free PMC article.
-
Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-γ Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination.Clin Infect Dis. 2022 Aug 24;75(1):e338-e346. doi: 10.1093/cid/ciab1021. Clin Infect Dis. 2022. PMID: 34893816 Free PMC article.
-
[Evolution of IGRA researches].Kekkaku. 2008 Sep;83(9):641-52. Kekkaku. 2008. PMID: 18979999 Review. Japanese.
-
Long-standing COVID-19 Disease in Immunocompromised and Immunocompetent Patients; Case Reports and Literature Review.Iran J Allergy Asthma Immunol. 2024 Jul 27;23(4):457-466. doi: 10.18502/ijaai.v23i4.16219. Iran J Allergy Asthma Immunol. 2024. PMID: 39549298 Review.
Cited by
-
A two-arm analysis of the immune response to heterologous boosting of inactivated SARS-CoV-2 vaccines.Sci Rep. 2023 Oct 31;13(1):18762. doi: 10.1038/s41598-023-46053-8. Sci Rep. 2023. PMID: 37907584 Free PMC article.
-
Assessing SARS-CoV-2-specific T-cell reactivity in late convalescents and vaccinees: Comparison and combination of QuantiFERON and activation-induced marker assays, and relation with antibody status.PLoS One. 2023 May 23;18(5):e0285728. doi: 10.1371/journal.pone.0285728. eCollection 2023. PLoS One. 2023. PMID: 37220145 Free PMC article.
-
Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose.Int J Mol Sci. 2023 May 10;24(10):8525. doi: 10.3390/ijms24108525. Int J Mol Sci. 2023. PMID: 37239872 Free PMC article.
-
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects.Viruses. 2023 May 30;15(6):1276. doi: 10.3390/v15061276. Viruses. 2023. PMID: 37376576 Free PMC article.
-
A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.J Neurol. 2023 May;270(5):2380-2391. doi: 10.1007/s00415-023-11575-8. Epub 2023 Mar 18. J Neurol. 2023. PMID: 36933032 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous